Business Context and Reporting Period
Company: Cognition Therapeutics, Inc. (CGTX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 21, 2026
Reporting Period: Single event date (May 21, 2026)
Business Context: The Company is an emerging growth company focused on developing treatments for neurological disorders. This filing reports a specific regulatory milestone regarding its lead candidate, zervimesine.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Regulatory Milestone: On May 21, 2026, the Company completed a meeting with the U.S. Food and Drug Administration (FDA).
Subject: The meeting concerned zervimesine for the treatment of dementia with Lewy bodies (DLB) in patients with psychosis.
Comparison: No prior comparable period data is provided in this filing to assess material changes in financial performance.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the FDA meeting but does not include specific guidance, future financial outlook, or detailed management commentary within the text of the 8-K itself.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the inherent uncertainty of regulatory interactions. The outcome of the FDA meeting is a key contingency for the development of zervimesine.
Investor Verification Checklist
- Review the full text of the press release filed as Exhibit 99.1 for specific details on the FDA meeting outcomes.
- Verify the Company's cash runway and liquidity position in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor subsequent filings for any updates on the FDA's feedback regarding zervimesine for dementia with Lewy bodies.
- Confirm the Company's status as an emerging growth company and any associated reporting exemptions.